HUP0500871A3 - 5-aryltetrazole compounds, compositions thereof and their use - Google Patents

5-aryltetrazole compounds, compositions thereof and their use

Info

Publication number
HUP0500871A3
HUP0500871A3 HU0500871A HUP0500871A HUP0500871A3 HU P0500871 A3 HUP0500871 A3 HU P0500871A3 HU 0500871 A HU0500871 A HU 0500871A HU P0500871 A HUP0500871 A HU P0500871A HU P0500871 A3 HUP0500871 A3 HU P0500871A3
Authority
HU
Hungary
Prior art keywords
compositions
aryltetrazole compounds
aryltetrazole
compounds
Prior art date
Application number
HU0500871A
Other languages
English (en)
Original Assignee
Inotek Pharmaceuticals Corp Be
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp Be filed Critical Inotek Pharmaceuticals Corp Be
Publication of HUP0500871A2 publication Critical patent/HUP0500871A2/hu
Publication of HUP0500871A3 publication Critical patent/HUP0500871A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0500871A 2002-07-18 2003-07-17 5-aryltetrazole compounds, compositions thereof and their use HUP0500871A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/197,609 US7078423B2 (en) 2002-07-18 2002-07-18 5-Aryltetrazole compounds, compositions thereof, and uses therefor
PCT/US2003/022462 WO2004009563A1 (en) 2002-07-18 2003-07-17 5-aryltetrazole compounds, compositions thereof, and uses therefor

Publications (2)

Publication Number Publication Date
HUP0500871A2 HUP0500871A2 (hu) 2005-12-28
HUP0500871A3 true HUP0500871A3 (en) 2006-11-28

Family

ID=30769479

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500871A HUP0500871A3 (en) 2002-07-18 2003-07-17 5-aryltetrazole compounds, compositions thereof and their use

Country Status (16)

Country Link
US (1) US7078423B2 (hu)
EP (1) EP1542980A1 (hu)
JP (1) JP2005535678A (hu)
KR (1) KR20050028038A (hu)
CN (1) CN1694875A (hu)
AU (1) AU2003249313A1 (hu)
BR (1) BR0312768A (hu)
CA (1) CA2492847A1 (hu)
HU (1) HUP0500871A3 (hu)
IL (1) IL166331A0 (hu)
MX (1) MXPA05000765A (hu)
NZ (1) NZ538313A (hu)
PL (1) PL374833A1 (hu)
RU (1) RU2005104429A (hu)
WO (1) WO2004009563A1 (hu)
ZA (1) ZA200501431B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
CN103159692B (zh) * 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 四唑取代的芳基酰胺类
WO2008064015A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
JP5378988B2 (ja) * 2007-04-11 2013-12-25 キッセイ薬品工業株式会社 ５員環へテロ環誘導体及びその医薬用途
KR101186704B1 (ko) * 2007-10-04 2012-09-27 에프. 호프만-라 로슈 아게 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도
NZ588374A (en) 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
US8293925B2 (en) * 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
US9918964B2 (en) * 2010-04-23 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
WO2014079850A1 (en) * 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
WO2016187521A1 (en) * 2015-05-21 2016-11-24 South Connecticut State University 5-substituted 1 h-tetrazole compounds, methods of synthesizing and therapeutic use
SG11202005278PA (en) * 2017-12-29 2020-07-29 Agency Science Tech & Res Compounds for treating eye diseases and methods thereof
KR20220054286A (ko) * 2019-06-25 2022-05-02 시놉세 테라페우틱스 눈 장애의 치료를 위한 화합물
CN112047896B (zh) * 2020-10-12 2022-06-17 上海麦克林生化科技有限公司 芳环基或芳杂环基四氮唑的合成方法
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049572A (en) * 1987-04-06 1991-09-17 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
US5284954A (en) * 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
IT1256870B (it) 1992-02-13 1995-12-27 Rotta Research Lab Derivati bis-tetrazolici ad attivita' antiallergica e citoprotettiva
US5364869A (en) * 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995031445A1 (fr) * 1994-05-16 1995-11-23 Sumitomo Chemical Company, Limited Procede pour produire un compose de tetrazole et intermediaire prevu a cet effet
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
DE69716424T2 (de) * 1996-05-24 2003-02-20 Neurosearch A/S, Ballerup Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
US6696475B2 (en) * 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
CN1118462C (zh) * 1997-04-22 2003-08-20 神经研究公司 取代的苯基衍生物、其制备方法以及用途
DE69816298T2 (de) 1997-06-19 2004-05-27 British Telecommunications P.L.C. Tonwiedergabesystem
DE69722610T2 (de) * 1997-08-08 2004-04-29 Rotta Research Laboratorium S.P.A., Monza Neue Inhalationspräparate enthaltend CR 2039 (Andolast)
US6191136B1 (en) * 1997-11-07 2001-02-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
CA2309792A1 (en) 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
ZA200101824B (en) * 1998-10-22 2002-03-05 Neurosearch As Substituted phenyl derivatives, their preparation and use.
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
CN1331862C (zh) 1999-04-28 2007-08-15 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
US6281222B1 (en) * 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
MXPA02007603A (es) 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
JP2004501913A (ja) * 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
JP4554207B2 (ja) * 2001-09-14 2010-09-29 ノボ ノルディスク アクティーゼルスカブ Ｒ状態のインスリン六量体におけるＨｉｓＢ１０Ｚｎ２＋部位のための新規なリガンド

Also Published As

Publication number Publication date
PL374833A1 (en) 2005-10-31
AU2003249313A1 (en) 2004-02-09
HUP0500871A2 (hu) 2005-12-28
IL166331A0 (en) 2006-01-16
US20040019208A1 (en) 2004-01-29
JP2005535678A (ja) 2005-11-24
ZA200501431B (en) 2006-02-22
CN1694875A (zh) 2005-11-09
MXPA05000765A (es) 2005-10-19
EP1542980A1 (en) 2005-06-22
US7078423B2 (en) 2006-07-18
NZ538313A (en) 2005-09-30
RU2005104429A (ru) 2005-08-27
KR20050028038A (ko) 2005-03-21
WO2004009563A1 (en) 2004-01-29
CA2492847A1 (en) 2004-01-29
BR0312768A (pt) 2005-05-10

Similar Documents

Publication Publication Date Title
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
EP1542699A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
AU2003270015A8 (en) Compounds, compositions, and methods
EP1646382A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
AU2003299612A8 (en) Compounds, compositions and methods
IL164581A0 (en) Compounds, compositions and methods
HUP0500871A3 (en) 5-aryltetrazole compounds, compositions thereof and their use
GB0203421D0 (en) Composition
IL167936A0 (en) Compounds, compositions,and methods
AU2003290507A8 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
EP1675834A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1594849A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
EP1680420A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0307695D0 (en) Compounds,compositions and processes
GB0203280D0 (en) Anti-glycolytic composition
EP1620092A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AU2003267169A8 (en) Compounds, compositions and methods
AU2003300031A8 (en) Compounds, compositions, and methods
EP1706111A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1622878A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees